Citigroup Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $44.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price decreased by analysts at Citigroup from $45.00 to $44.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 103.33% from the stock’s current price.

APLS has been the topic of several other research reports. Wolfe Research started coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating on the stock. Needham & Company LLC reduced their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. lowered their price objective on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Wedbush reduced their target price on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $32.61.

Apellis Pharmaceuticals Trading Up 1.0%

Shares of Apellis Pharmaceuticals stock opened at $21.64 on Wednesday. The company has a fifty day simple moving average of $23.07 and a 200-day simple moving average of $23.81. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $30.48. The company has a current ratio of 3.14, a quick ratio of 3.10 and a debt-to-equity ratio of 0.98. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of 166.47 and a beta of 0.26.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.86. The firm had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. Apellis Pharmaceuticals’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) earnings per share. On average, equities analysts forecast that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other news, CFO Timothy Eugene Sullivan sold 10,287 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $223,947.99. Following the completion of the sale, the chief financial officer owned 93,901 shares in the company, valued at approximately $2,044,224.77. This trade represents a 9.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 27,192 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the transaction, the chief executive officer owned 286,045 shares in the company, valued at approximately $6,227,199.65. This trade represents a 8.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 120,537 shares of company stock worth $2,608,532 in the last 90 days. Corporate insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of APLS. Jones Financial Companies Lllp boosted its stake in shares of Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after buying an additional 1,373 shares in the last quarter. Osaic Holdings Inc. raised its position in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares in the last quarter. Allworth Financial LP lifted its holdings in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares during the period. Quantbot Technologies LP acquired a new stake in Apellis Pharmaceuticals in the third quarter valued at $64,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 338.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long‑range outlook (FY2030 EPS to $1.97), reiterated a “Buy” and lifted its price target to $48 — a strongly bullish signal that likely supported buying interest this session. HC Wainwright raises target to $48
• Neutral Sentiment: Citigroup trimmed its target from $45 to $44 but kept a “Buy” rating — a modestly cautious move that is unlikely to materially change conviction among bullish investors. Citigroup price target update
• Neutral Sentiment: Earnings/transcript sources for the Feb. 24 Q4 call are circulating (full transcript available) — the call contains detail investors will parse for guidance and product trends; headlines are mixed across outlets. Earnings call transcript (Yahoo) Earnings call transcript (InsiderMonkey)
• Neutral Sentiment: Short‑interest data released shows “0 shares” and NaN changes — this is almost certainly a reporting or processing error and should not be treated as a genuine change in borrow/short pressure.
• Negative Sentiment: Royal Bank of Canada cut its target to $21 and moved to “Sector Perform,” which signals lower near‑term expectations and adds selling pressure for more cautious holders. RBC target cut Coverage note
• Negative Sentiment: Wedbush lowered its target to $18 and moved to “Neutral,” another sign of reduced analyst conviction that could weigh on the stock if follow‑through selling occurs. Wedbush target cut Coverage note
• Negative Sentiment: Zacks flagged a wider‑than‑expected Q4 loss and an 8% slip in Syfovre sales (though total revenue beat estimates and Empaveli grew on a new indication) — mixed results that may keep some investors cautious until product trends clarify. Zacks earnings summary

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.